DTC
ENTA icon

Deep Track Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Deep Track Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.7M Hold
1,956,867
– – 0.4% 49
2025
Q4 		$30.9M Buy
+1,956,867
New +$24.9M 0.55% 38
2022
Q2 		– Sell
-198,730
Closed -$14.1M – 54
2022
Q1 		$14.1M Buy
+198,730
New +$12.9M 0.91% 32

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deep Track Capital's ENTA Position: Q1 2026 in Review

Deep Track Capital held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 1,956,867 shares worth $24.7M. The position accounts for 0.4% of the portfolio, ranked #49.

Deep Track Capital first reported a position in ENTA in Q1 2022 and has held it in 3 quarters since. The position peaked at $30.9M in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Deep Track Capital held 1,956,867 shares of Enanta Pharmaceuticals worth $24.7M as of Q1 2026.
  • Deep Track Capital left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
  • Enanta Pharmaceuticals made up 0.4% of Deep Track Capital's portfolio in Q1 2026, its #49 holding.
  • Deep Track Capital first reported a position in Enanta Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • Deep Track Capital's Enanta Pharmaceuticals position peaked at $30.9M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.